All In Biotech

Drug Trial Radar · NCT07684742

Early Single Antiplatelet Therapy After IVUS-Guided PCI in Acute Coronary Syndrome

Early Single Antiplatelet Therapy With a Potent P2Y12 Inhibitor After Intravascular Ultrasound-Guided PCI in Patients With Acute Coronary Syndrome: A Multicenter Randomized Controlled Trial

Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 2,200 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

2,200

Planned (sponsor's estimate)

Start

Jul 1, 2026

Primary completion

Jul 1, 2031

Study completion Jan 31, 2033

Sponsor

Lead sponsor
Gyeongsang National University HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Genoss Co., Ltd.; CGBio Inc.; Osstem vascular; Dio
First posted
Jul 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, open-label, multicenter, randomized, phase IV clinical trial designed to evaluate the safety and efficacy of early aspirin discontinuation followed by potent P2Y12 inhibitor monotherapy after intravascular ultrasound (IVUS)-guided drug-eluting stent implantation in patients with acute coronary syndrome. A total of 2,200 patients who achieve complete revascularization after IVUS-guided percutaneous coronary intervention (PCI) and meet the predefined successful IVUS-guided PCI criteria will be randomized in a 1:1 ratio to either the early single antiplatelet therapy group (Early SAPT: ticagrelor or prasugrel monotherapy) or the standard dual antiplatelet therapy group (Standard DAPT: aspirin plus ticagrelor or prasugrel). Randomization will be performed within 96 hours after completion of PCI, and clinical follow-up will be conducted at 1 month, 3 months, 6 months, and 12 months after randomization. The primary endpoints are major adverse cardiovascular events, defined as a composite of all-cause death, myocardial infarction, ischemia-driven target vessel revascularization, and definite or probable stent thrombosis occurring up to 12 months after randomization, and clinically relevant bleeding, defined as Bleeding Academic Research Consortium (BARC) type 2, 3, or 5 bleeding occurring up to 12 months after randomization. This study aims to determine whether early P2Y12 inhibitor monotherapy is non-inferior to standard dual antiplatelet therapy (DAPT) for ischemic events and is superior in reducing clinically relevant bleeding.

Conditions

  • Acute Coronary Syndromes
  • STEMI
  • NSTEMI
  • Unstable Angina

Interventions

  • Early P2Y12 Inhibitor MonotherapyDrug

    Participants randomized within 96 hours after successful IVUS-guided PCI will discontinue aspirin immediately after randomization and receive potent P2Y12 inhibitor monotherapy with ticagrelor 90 mg twice daily or prasugrel 10 mg once daily. However, in patients aged ≥75 years, weighing \<60 kg, or considered at high bleeding risk, a reduced dose of ticagrelor (60 mg twice daily) or prasugrel (5 mg once daily) may be administered at the operator's discretion.

  • Standard Dual Antiplatelet TherapyDrug

    Participants randomized within 96 hours after successful IVUS-guided PCI will receive aspirin 100 mg once daily plus a potent P2Y12 inhibitor, consisting of ticagrelor 90 mg twice daily or prasugrel 10 mg once daily, for 12 months. However, in patients aged ≥75 years, weighing \<60 kg, or considered at high bleeding risk, a reduced dose of ticagrelor (60 mg twice daily) or prasugrel (5 mg once daily) may be administered at the operator's discretion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Major Adverse Cardiovascular EventsTime frame: Up to 12 months after randomization
  2. Clinically Relevant BleedingTime frame: Up to 12 months after randomization

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Gyeongsang National University Hospital

    Jinju, Gyeongsangnam-do, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.